240 related articles for article (PubMed ID: 17766367)
1. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
Lüdtke A; Buettner J; Schmidt HH; Worman HJ
J Med Genet; 2007 Sep; 44(9):e88. PubMed ID: 17766367
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.
Lüdtke A; Buettner J; Wu W; Muchir A; Schroeter A; Zinn-Justin S; Spuler S; Schmidt HH; Worman HJ
J Clin Endocrinol Metab; 2007 Jun; 92(6):2248-55. PubMed ID: 17356052
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.
Auclair M; Vigouroux C; Boccara F; Capel E; Vigeral C; Guerci B; Lascols O; Capeau J; Caron-Debarle M
Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):829-38. PubMed ID: 23393388
[TBL] [Abstract][Full Text] [Related]
4. A Pharmacogenetic Approach to the Treatment of Patients With
Agostini M; Schoenmakers E; Beig J; Fairall L; Szatmari I; Rajanayagam O; Muskett FW; Adams C; Marais AD; O'Rahilly S; Semple RK; Nagy L; Majithia AR; Schwabe JWR; Blom DJ; Murphy R; Chatterjee K; Savage DB
Diabetes; 2018 Jun; 67(6):1086-1092. PubMed ID: 29622583
[TBL] [Abstract][Full Text] [Related]
5. Impaired peroxisome proliferator-activated receptor gamma function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy.
Jeninga EH; van Beekum O; van Dijk AD; Hamers N; Hendriks-Stegeman BI; Bonvin AM; Berger R; Kalkhoven E
Mol Endocrinol; 2007 May; 21(5):1049-65. PubMed ID: 17312272
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of the transactivation deficiency of the human PPARγ F360L mutant associated with familial partial lipodystrophy.
Lori C; Pasquo A; Montanari R; Capelli D; Consalvi V; Chiaraluce R; Cervoni L; Loiodice F; Laghezza A; Aschi M; Giorgi A; Pochetti G
Acta Crystallogr D Biol Crystallogr; 2014 Jul; 70(Pt 7):1965-76. PubMed ID: 25004973
[TBL] [Abstract][Full Text] [Related]
7. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma.
Monajemi H; Zhang L; Li G; Jeninga EH; Cao H; Maas M; Brouwer CB; Kalkhoven E; Stroes E; Hegele RA; Leff T
J Clin Endocrinol Metab; 2007 May; 92(5):1606-12. PubMed ID: 17299075
[TBL] [Abstract][Full Text] [Related]
8. Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -γ (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations.
Demir T; Onay H; Savage DB; Temeloglu E; Uzum AK; Kadioglu P; Altay C; Ozen S; Demir L; Cavdar U; Akinci B
Diabet Med; 2016 Oct; 33(10):1445-50. PubMed ID: 26756202
[TBL] [Abstract][Full Text] [Related]
9. Lessons from human mutations in PPARgamma.
Hegele RA
Int J Obes (Lond); 2005 Mar; 29 Suppl 1():S31-5. PubMed ID: 15711581
[TBL] [Abstract][Full Text] [Related]
10. Thiazolidinedione response in familial lipodystrophy patients with LMNA mutations: a case series.
Luedtke A; Boschmann M; Colpe C; Engeli S; Adams F; Birkenfeld AL; Haufe S; Rahn G; Luft FC; Schmidt HH; Jordan J
Horm Metab Res; 2012 Apr; 44(4):306-11. PubMed ID: 22274718
[TBL] [Abstract][Full Text] [Related]
11. Novel peroxisome proliferator-activated receptor gamma mutation in a family with familial partial lipodystrophy type 3.
Miehle K; Porrmann J; Mitter D; Stumvoll M; Glaser C; Fasshauer M; Hoffmann K
Clin Endocrinol (Oxf); 2016 Jan; 84(1):141-8. PubMed ID: 26119484
[TBL] [Abstract][Full Text] [Related]
12. Vascular placental abnormalities and newborn death in a pregnant diabetic woman with familial partial lipodystrophy type 3: a possible role for peroxisome proliferator-activated receptor γ.
Castell AL; Hiéronimus S; Lascols O; Fournier T; Fénichel P
Diabetes Metab; 2012 Oct; 38(4):367-9. PubMed ID: 22559930
[TBL] [Abstract][Full Text] [Related]
13. The novel loss of function Ile354Val mutation in PPARG causes familial partial lipodystrophy.
Padova G; Prudente S; Vinciguerra F; Sudano D; Baratta R; Bellacchio E; Trischitta V; Vallone A; Sciacca L; Frittitta L
Acta Diabetol; 2020 May; 57(5):589-596. PubMed ID: 31863320
[TBL] [Abstract][Full Text] [Related]
14. Natural helix 9 mutants of PPARγ differently affect its transcriptional activity.
Broekema MF; Massink MPG; Donato C; de Ligt J; Schaarschmidt J; Borgman A; Schooneman MG; Melchers D; Gerding MN; Houtman R; Bonvin AMJJ; Majithia AR; Monajemi H; van Haaften GW; Soeters MR; Kalkhoven E
Mol Metab; 2019 Feb; 20():115-127. PubMed ID: 30595551
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor gamma-ligand-binding domain mutations associated with familial partial lipodystrophy type 3 disrupt human trophoblast fusion and fibroblast migration.
Shoaito H; Chauveau S; Gosseaume C; Bourguet W; Vigouroux C; Vatier C; Pienkowski C; Fournier T; Degrelle SA
J Cell Mol Med; 2020 Jul; 24(13):7660-7669. PubMed ID: 32519441
[TBL] [Abstract][Full Text] [Related]
16. Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma.
Tsukahara T; Tsukahara R; Yasuda S; Makarova N; Valentine WJ; Allison P; Yuan H; Baker DL; Li Z; Bittman R; Parrill A; Tigyi G
J Biol Chem; 2006 Feb; 281(6):3398-407. PubMed ID: 16321982
[TBL] [Abstract][Full Text] [Related]
17. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy.
Hegele RA; Cao H; Frankowski C; Mathews ST; Leff T
Diabetes; 2002 Dec; 51(12):3586-90. PubMed ID: 12453919
[TBL] [Abstract][Full Text] [Related]
18. Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators.
Hamuro Y; Coales SJ; Morrow JA; Molnar KS; Tuske SJ; Southern MR; Griffin PR
Protein Sci; 2006 Aug; 15(8):1883-92. PubMed ID: 16823031
[TBL] [Abstract][Full Text] [Related]
19. Inguinal Fat Compensates Whole Body Metabolic Functionality in Partially Lipodystrophic Mice with Reduced PPARγ Expression.
Chang CS; Yu SS; Ho LC; Chao SH; Chou TY; Shao AN; Kao LZ; Chang CY; Chen YH; Wu MS; Tsai PJ; Maeda N; Tsai YS
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835312
[TBL] [Abstract][Full Text] [Related]
20. Functional implications of genetic variation in human PPARgamma.
Jeninga EH; Gurnell M; Kalkhoven E
Trends Endocrinol Metab; 2009 Oct; 20(8):380-7. PubMed ID: 19748282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]